Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences (EW) to $83 from $81 and keeps a Neutral rating on the shares. The firm updated its model following results which saw TAVR growth hit double digits but the TMTT and suspected TAVR deceleration keeps them on the sidelines for now.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $100 from $90 at Mizuho
- Edwards Lifesciences price target raised to $95 from $90 at Piper Sandler
- Edwards Lifesciences price target raised to $96 from $95 at Citi
- Edwards Lifesciences price target raised to $99 from $95 at Barclays
- Edwards Lifesciences Reports Strong Q3 2025 Growth